OSE Immunotherapeutics Investor Relations Material

OSE Immunotherapeutics SA is a French biotechnology company focused on developing immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company’s pipeline includes innovative treatments aimed at modulating the immune system, including checkpoint inhibitors, therapeutic vaccines, and monoclonal antibodies. OSE Immunotherapeutics leverages proprietary technology platforms to design therapies that target specific immune pathways, with the goal of improving patient outcomes in conditions where immune response plays a critical role. The company collaborates with research institutions and pharmaceutical companies to advance its clinical programs. The company is headquartered in Nantes, France, and its shares are listed on Euronext Paris.